iGlarLixi CGM Study in Chinese T2D Individuals After OADs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 678 participants.

Also called NCT06671587

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 678 participants (planned count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06671587
  • WHO UTN U1111-1306-6660
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06671587. Randomized; no masking; primary purpose treatment. Start 2024-12-10 (actual); primary completion 2026-09-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Acronym
China Soli-CGM
Condition
Type 2 Diabetes (T2D)
Intervention (Drug)
iGlarLixi (insulin glargine/lixisenatide)
Intervention (Drug)
Gla-100 (insulin glargine)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct06671587
Content hash
f9e60215e0bdb291d40d16fdb1fa75cc16c956cbdedab397787357c02b92f749